On June 11, 2026 Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, reported that two of its clinical-stage immunotherapy programs will be presented at the New York Academy of Sciences’ Frontiers in Cancer Immunotherapy symposium, being held June 22 – 23, 2026, at Memorial Sloan Kettering Cancer Center in New York City.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentations will highlight Anixa’s ovarian cancer CAR-T therapy, liraltagene autoleucel, or lira-cel, which is being evaluated in an ongoing Phase 1 clinical trial, and Anixa’s breast cancer vaccine program, which completed a Phase 1 clinical trial in which all major primary endpoints were met and protocol-defined immune responses were generated in 74% of participants.

Frontiers in Cancer Immunotherapy brings together leading researchers, clinicians and industry innovators to explore next-generation therapies that are transforming cancer treatment. The symposium will showcase research and emerging approaches in areas including cancer vaccines, bispecifics, modulation of the tumor microenvironment, AI-driven discovery of immunotherapy and cell-based therapies for solid tumors. Additionally, Dr. Stephen Schoenberger, PhD, a world-renowned immunologist at the La Jolla Institute for Immunology and a member of Anixa’s Clinical Advisory Board, will be a featured speaker at the symposium.

"Presenting both of our clinical-stage immunotherapy programs at this symposium is an important opportunity to highlight the progress of our pipeline and the strength of the collaborations supporting these programs," said Dr. Amit Kumar, PhD, Chairman and CEO of Anixa Biosciences. "Our ovarian cancer CAR-T therapy and breast cancer vaccine program are being advanced with leading clinical and scientific institutions, and we believe these presentations underscore the potential of Anixa’s approach to treating and preventing cancer."

The Company’s lira-cel presentation, titled "A Phase I Clinical Trial of an Infusion of Autologous T cells Genetically Engineered with a Chimeric Receptor to Target the Follicle-Stimulating Hormone Receptor in Patients with Recurrent Ovarian Cancer," will be given by Dr. Pamela D. Garzone, PhD, Chief Development Officer of Anixa Biosciences. The presentation will report the clinical trial design and objectives, as well as the current status of Anixa’s ongoing Phase 1 clinical trial of lira-cel.

The lira-cel presentation reflects contributions from investigators and collaborators across Anixa, Moffitt Cancer Center, Roswell Park Cancer Center, the University of Chicago School of Medicine and Duke University Medical Center. Project team members cited on the poster include:

Dr. Marco L. Davila, MD, PhD (Department of Medicine, Roswell Park Cancer Center)
Dr. Daniel Abate-Daga, PhD (Department of Immunology, Moffitt Cancer Center)
Dr. Melissa McGettigan, MD (Department of Radiology, Moffitt Cancer Center)
Dr. Xuefeng Wang, PhD (Department of Biostatistics and Bioinformatics, Moffitt Cancer Center)
Dr. Theresa Boyle, MD, PhD (Department of Pathology, Moffitt Cancer Center)
Dr. Amit Kumar, PhD (Anixa Biosciences, Inc.)
Denise Dorman, RN (Department of Gynecologic Oncology, Moffitt Cancer Center)
Dr. Richard Koya, MD, PhD (University of Chicago School of Medicine)
Dr. Christopher Cubitt, PhD (Immune Monitoring Core, Moffitt Cancer Center)
Dr. Jose Conejo-Garcia, MD, PhD (Department of Immunology, Duke University Medical Center)
Dr. Robert M. Wenham, MD, MS (Principal Investigator, Department of Gynecologic Oncology, Moffitt Cancer Center)
The Company’s breast cancer vaccine presentation, titled "Phase I Trial of an Alpha-Lactalbumin (aLA) Vaccine for Breast Cancer," will be given by Dr. Emily Esakov Rhoades, PhD, FDA/IND Trial Program Manager, Cleveland Clinic Cancer Institute. The presentation will report final Phase 1 findings for the investigational vaccine, including that all major primary endpoints were met, the vaccine was safe and well tolerated at the maximum tolerated dose based on safety and tolerability, and protocol-defined immune responses were elicited in 74% of trial participants. Immunohistochemistry of tumor samples demonstrating alpha-lactalbumin expression will also be reported.

The breast cancer vaccine presentation reflects contributions from Cleveland Clinic clinicians, translational researchers, patient advocates, and collaborators involved in advancing the program. The Cleveland Clinic team includes:

Dr. Justin M. Johnson, PhD (Department of Inflammation & Immunity, Cleveland Clinic)
Holly B. Levengood (Department of Inflammation & Immunity, Cleveland Clinic Cancer Institute)
Dr. Azka Ali, MD (Cleveland Clinic Cancer Institute)
Dr. Hannah Gilmore, MD (Robert J. Tomsich Pathology and Laboratory Medicine Institute)
Dr. Megan L. Kruse, MD (Cleveland Clinic Cancer Institute)
Dr. Erin E. Roesch, MD (Cleveland Clinic Cancer Institute)
Dr. Tiffany Onger, MD (Cleveland Clinic Cancer Institute)
Brenna Elliott (Cleveland Clinic Cancer Institute)
Elena Haury (Cleveland Clinic Cancer Institute)
Carolyn Porvasnik (Cleveland Clinic Cancer Institute)
Tobey Young (Previvorsandsurvivors.com, Inc.)
Terri Coutee (DiepCJourney Foundation)
Judith A. Fitzgerald, BCPA (Sisters4Prevention)
Dr. Thaddeus S. Stappenbeck, MD, PhD (Co-Principal Investigator, Chair – Department of Inflammation & Immunity, Cleveland Clinic)
Dr. G. Thomas Budd, MD (Principal Investigator, Cleveland Clinic Cancer Institute)
About Lira-cel, Anixa’s CAR-T Therapy for Recurrent Ovarian Cancer
Liraltagene autoleucel, or lira-cel, uniquely targets the follicle-stimulating hormone receptor (FSHR), which is selectively expressed on ovarian and testis cells, tumor vasculature, and certain cancer cells, but not in other healthy tissue. The ongoing Phase 1 trial (ClinicalTrials.gov NCT05316129) is enrolling adult women with recurrent ovarian cancer who are platinum resistant and have progressed after at least two prior therapies.

(Press release, Anixa Biosciences, JUN 11, 2026, View Source [SID1234666580])